TRIUS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Trius Therapeutics, Inc. Following Announcement Of Proposed Sale Of Company To Cubist Pharmaceuticals, Inc.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) announce that KSF has commenced an investigation into the Board of Directors of Trius Therapeutics, Inc. (“Trius” or the “Company”) (NASDAQ GM: TSRX) in connection with their conduct related to the sale of the Company to Cubist Pharmaceuticals, Inc. (NASDAQ GS: CBST). Under the terms of the proposed transaction, shareholders of Trius will receive $13.50 in cash for each share of Trius common stock that they own. In addition, each Trius shareholder will receive one contingent value right entitling the holder to receive an additional cash payment of up to $2.00 for each share that they own if certain commercial sales milestones are achieved.

KSF’s investigation is focusing on whether Trius and/or its officers and directors secured sufficient value for the shareholders of the Company, violated their fiduciary duties, and/or violated state or federal securities laws.

If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( or attorney Michael Palestina ( toll free at 855-768-1857 or via cell phone any time at 504-236-7315.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on transactional litigation, as well as securities class action and shareholder derivative litigation. With offices in New York and Louisiana, KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.

To learn more about KSF, you may visit

Copyright Business Wire 2010

If you liked this article you might like

Cramer's 'Mad Money' Recap: Disciplined Investors Rule

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Cramer Quick Take: What's Next for Biotech?

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys